NASDAQ:SMTI

Sanara MedTech Q3 2026 Earnings Results & Report

Sanara MedTech logo
$32.74 +0.01 (+0.03%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sanara MedTech was expected to report Q3 2026 earnings on November 12, 2026, after market closes. Analysts expected earnings of $0.06 per share on revenue of $29.30 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Earnings Announcement Details

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
7:00 AM ET

Sanara MedTech EPS Results

Actual EPS
N/A
Consensus EPS
$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 7 quarters

Sanara MedTech Revenue Results

Actual Revenue
N/A
Expected Revenue
$29.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sanara MedTech Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Reviewing Sanara MedTech (SMTI) and The Competition
See More Sanara MedTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sanara MedTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sanara MedTech and other key companies, straight to your email.

About Sanara MedTech

Sanara MedTech (NASDAQ:SMTI), Inc. develops, markets and distributes medical products for wound care, surgical tissue repair and related applications. Its offerings are intended for use by healthcare professionals treating acute and chronic wounds and supporting tissue healing.

The company’s portfolio includes CellerateRX® collagen-based products and BIAKŌS® antimicrobial products, along with other solutions for wound and surgical care. Sanara sells its products to healthcare providers and through distribution channels.

View Sanara MedTech Profile